STOCK TITAN

Ovid Therapeutics (OVID) Stock News, Oct 2023-Jun 2024

OVID NASDAQ

Ovid Therapeutics Inc. reports developments as a biopharmaceutical company developing targeted small-molecule medicines for brain disorders and symptoms linked to excess neural excitability. Recurring news centers on its KCC2 direct-activator portfolio, including OV350, OV4071 and next-generation candidates, as well as OV329, a next-generation GABA-aminotransferase inhibitor being developed for treatment-resistant seizures and related rare epileptic disorders.

Company updates also cover clinical and translational data, regulatory clearances for early-stage studies, R&D events, financial results, private-placement and warrant-related capital actions, investor conference participation, and leadership or governance changes tied to the advancement of its CNS pipeline.

Rhea-AI Summary

Ovid Therapeutics reported on Takeda's Phase 3 study results for soticlestat, a treatment for Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS). The Skyline study in DS narrowly missed its primary endpoint but showed significant effects in secondary endpoints with p-values ≤ 0.008. The Skyway study in LGS missed its primary endpoint. Soticlestat had a favorable safety profile across both studies. Takeda will discuss the total data with regulatory authorities. Ovid highlighted its differentiated pipeline and financial strategy, with cash runway expected to last into H1 2026. Key upcoming milestones include Phase 2 and Phase 1 trials for OV888, OV329, and the KCC2 direct activator OV350.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-76.00%
Tags
-
Rhea-AI Summary

Ovid Therapeutics (NASDAQ: OVID) has provided business updates and first-quarter 2024 financial results. Key highlights include the completion of two Phase 3 trials by Takeda for soticlestat, expected to treat Lennox-Gastaut and Dravet syndromes, with topline data anticipated in H1 2024. A Phase 1 trial for OV888 (GV101) has concluded, showing no serious adverse events, with Phase 2 set to begin in H2 2024. Financials reveal cash and equivalents of $90.3 million, enough to support operations into H1 2026. Revenue for Q1 2024 was $148,000, up from $66,000 in Q1 2023, despite an increased net loss of $11.7 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.95%
Tags
-
Rhea-AI Summary

Ovid Therapeutics Inc. will be participating in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference on May 20, 2024, at 3:00 p.m. ET. The company is focused on developing medicines for rare epilepsies and brain conditions. The event will be live webcasted and can be accessed through the Company’s website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.67%
Tags
conferences
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
conferences
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.84%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.51%
Tags
conferences
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.49%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.39%
Tags
conferences
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.13%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.13%
Tags
none

FAQ

What is the current stock price of Ovid Therapeutics (OVID)?

Ovid Therapeutics (OVID) last closed at $2.22.

What is the market cap of Ovid Therapeutics (OVID)?

The market cap of Ovid Therapeutics (OVID) is approximately $419.0M.